AVADEL PHARMACEUTICALS PLC 4

Weiss Asset Management LP, as a former 10% owner of Avadel Pharmaceuticals plc, had 11,112,052 ordinary shares cashed out at $21.00 per share in the acquisition by Alkermes plc.

On February 13, 2026, Weiss Asset Management LP, reported as a former 10% owner of Avadel Pharmaceuticals plc, disposed of 11,112,052 ordinary shares in connection with the closing of Avadel’s acquisition by Alkermes plc, in which each outstanding Avadel share was automatically converted into the right to receive $21.00 in cash plus a contingent value right for an additional $1.50 per share upon achievement of a specified milestone. The transaction, structured as a merger consideration event and coded as a sale, represents a cash-out of Weiss’s fund-held stake rather than an open-market discretionary sale, with aggregate cash consideration of approximately $233.35 million excluding any future CVR payments. Following the transaction, Weiss Asset Management and related reporting persons ceased to be 10% owners, with the reported holdings for this Form 4 position effectively reduced to zero, and all parties disclaim beneficial ownership beyond their pecuniary interests in the underlying funds.

Filing Facts

CIK

1012477

Ticker

AVDL

Form

4

Source Type

fda

Accession

0001357550-26-000015

Alert Tier

7